Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 25, 2011, Pages 10255-10259

  Bloom, Ona ^a   Cheng, Kai Fen ^b   He, Mingzhu ^b   Papatheodorou, Angelos ^a   Volpe, Bruce T ^c   Diamond, Betty ^d   Al Abed, Yousef ^d  

^a Center for Autoimmune and Musculoskeletal Diseases   (United States)

^b Department of Medicinal Chemistry   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Autoimmunity; Glomerolotoxicity; Neurotoxicity; Orally absorbable

Indexed keywords

ASPARTYLTRYPTOPHANYLGLUTAMYLTYROSYLSERINE; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; FISLE 412; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENTAPEPTIDE; PEPTIDOMIMETIC AGENT; TISSUE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PEPTIDES; PEPTIDOMIMETICS;

ANIMALIA;

EID: 79959960210     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1103555108     Document Type: Article

References (37)

1. Kotzin BL (1996) Systemic lupus erythematosus. Cell 85:303-306.
2. Waters ST, et al. (2004) Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 199:255-264. (Pubitemid 38129705)
3. Ebling F, Hahn BH (1980) Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus. Comparison of antibodies in serum and renal eluates. Arthritis Rheum 23:392-403.
4. Winfield JB, Faiferman I, Koffler D (1977) Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 59:90-96. (Pubitemid 8018043)
5. Pearson L, Lightfoot RW, Jr. (1981) Correlation of DNA-anti-DNA association rates with clinical activity in systemic lupus erythematosus (SLE). J Immunol 126:16-19.
6. Davis P, Cumming RH, Verrier-Jones J (1977) Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus. Clin Exp Immunol 28:226-232. (Pubitemid 8119968)
7. Bertsias GK, Salmon JE, Boumpas DT (2010) Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. Ann Rheum Dis 69:1603-1611.
8. Avalos AM, Busconi L, Marshak-Rothstein A (2010) Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43:76-83.
9. Clynes R, Dumitru C, Ravetch JV (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052-1054. (Pubitemid 28113310)
10. Park SY, et al. (1998) Resistance of Fc receptor- deficientmice to fatal glomerulonephritis. J Clin Invest 102:1229-1238. (Pubitemid 28436283)
11. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33:634-643.
12. Gaynor B, et al. (1997) Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci USA 94:1955-1960. (Pubitemid 27113943)
13. Katz JB, Limpanasithikul W, Diamond B (1994) Mutational analysis of an autoantibody: Differential binding and pathogenicity. J Exp Med 180:925-932. (Pubitemid 24256605)
14. Shefner R, Kleiner G, Turken A, Papazian L, Diamond B (1991) A novel class of anti-DNA antibodies identified in BALB/c mice. J Exp Med 173:287-296.
15. DeGiorgio LA, et al. (2001) A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7:1189-1193.
16. Faust TW, et al. (2010) Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci USA 107:18569-18574.
17. Kowal C, et al. (2004) Cognition and immunity; antibody impairs memory. Immunity 21:179-188. (Pubitemid 39094048)
18. Aranow C, Diamond B, Mackay M (2010) Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 36:187-201 x-xi.
19. Fragoso-Loyo H, et al. (2008) Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS ONE 3:e3347.
20. Fragoso-Loyo H, et al. (2009) Inflammatory profile in the cerebrospinal fluid of patients with central neuropsychiatric lupus, with and without associated factors. Rheumatology (Oxford) 48:1615-1616.
21. Husebye ES, et al. (2005) Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 64: 1210-1213. (Pubitemid 41113359)
22. Yoshio T, Onda K, Nara H, Minota S (2006) Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 54:675-678. (Pubitemid 43228647)
23. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B (2006) Immunity and behavior: Antibodies alter emotion. Proc Natl Acad Sci USA 103:678-683. (Pubitemid 43153085)
24. Kowal C, et al. (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 103:19854-19859. (Pubitemid 46037520)
25. Lee JY, et al. (2009) Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 15:91-96.
26. Zhang J, et al. (2009) Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun 33:270-274.
27. Mackay M, et al. (2006) Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 203:2157-2164. (Pubitemid 44352236)
28. McGaha TL, Karlsson MC, Ravetch JV (2008) FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol 180:5670-5679.
29. Dhodapkar KM, et al. (2007) Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204:1359-1369. (Pubitemid 46919874)
30. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV (2002) Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 195:1167-1174. (Pubitemid 34517142)
31. McGaha TL, Sorrentino B, Ravetch JV (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307:590-593. (Pubitemid 40165683)
32. Tchorbanov AI, et al. (2007) Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol 37:3587-3596.
33. Voynova E, et al. (2008) An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes. Immunol Lett 116:168-173.
34. Mihaylova N, et al. (2009) Simultaneous engagement of FcgammaIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. Mol Immunol 47:123-130.
35. Nikolova KA, et al. (2010) Selective silencing of autoreactive B lymphocytes-Following the Nature's way. Autoimmun Rev 9:775-779.
36. Tan H, Yang X, Cui S, Yang Z (2009) A novel pseudovirus encoding Diphtheriatoxin A fragment eliminates autoantibody-producing B cells and inhibits lupus in the BWF1 mouse model. Immunol Lett 126:43-47,
37. and retraction (2011) 136:114.